Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS)

被引：4

作者：

Sanders, J. ^{[1
]}

Crawford, B.

Gibson, J.

Ho, P. Joy

Iland, H.

Joshua, D.

机构：

[1] Royal Prince Alfred Hosp, Inst Haematol, Sydney, NSW, Australia

[2] Univ Sydney, Royal Prince Alfred Hosp, Dept Endocrinol, Sydney, NSW 2006, Australia

来源：

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2007年 / 29卷 / 05期

关键词：

D O I：

10.1111/j.1365-2257.2006.00860.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：395 / 397

页数：3

共 9 条

[1] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[2] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, M ;

Blacklock, H ;

Bell, R ;

Simeone, JF ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602

[3]

Corso A, 2001, HAEMATOLOGICA, V86, P394

[4] Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance [J].

Diamond, T ;

Levy, S ;

Smith, A ;

Day, P ;

Manoharan, A .

INTERNAL MEDICINE JOURNAL, 2001, 31 (05) :272-278

[5] Bone remodelation markers are useful in the management of monoclonal gammopathies [J].

Hernández, JM ;

Suquía, B ;

Queizan, JA ;

Fisac, RM ;

Sanchez, JJ ;

Fernández-Calvo, FJ ;

García-Sanz, R ;

Olivier, C ;

Bárez, A ;

Calmuntia, MJ ;

García-Frade, J ;

Portero, JA ;

López, R ;

Aguilera, C ;

Navajo, JA ;

San-Miguel, JF .

HEMATOLOGY JOURNAL, 2004, 5 (06) :480-488

[6] Bone disease in multiple myeloma: new markers, new treatments [J].

Joshua, D .

INTERNAL MEDICINE JOURNAL, 2001, 31 (05) :261-263

[7] Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect [J].

Martín, A ;

García-Sanz, R ;

Hernández, J ;

Bladé, J ;

Suquía, B ;

Fernández-Calvo, J ;

González, M ;

Mateo, G ;

Orfao, A ;

San Miguel, JF .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (01) :239-242

[8]

MCCLOSKEY EV, 1998, BRIT MED J, V30, P172

[9] Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases [J].

Ruggiero, SL ;

Mehrotra, B ;

Rosenberg, TJ ;

Engroff, SL .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (05) :527-534

← 1 →